Tandem Diabetes Care (TNDM) Environmental, Social & Governance (ESG) Data

Company Profile

Search within these filings

View filings

Exhibits within filings

Filing insights

Export filings list

Export a CSV file of filings or unique filing companies (up to first 5,000 results).

Download list of filings Download list of companies

Employees

Data from SEC filings

Employee count

CEO pay ratio

CEO Salary

Median Employee Salary

ESG framework mentions

In last year of SEC filings

Sustainability Accounting Standards Board (SASB)

No mentions

Global Reporting Initiative (GRI)

No mentions

Task Force on Climate-related Financial Disclosures (TCFD)

No mentions

UN Sustainable Development Goals (SDGs)

No mentions

ESG term mentions

In last year of SEC filings

Air Carbon Carbon Emissions Climate Climate Change Ecosystem Emission Environment Environmental Extreme Weather Green Landfill LEED Lifecycle Materials Mineral Nature Net Zero Offset Package Packaging Pandemic Plastic Pollution Raw Materials Recycling Solar Waste Water Access Affordability Asian Benefits Black California Consumer Privacy Act Charitable Child Labor Collective Bargaining Community Culture Customer Customer Satisfaction Cyber Cybersecurity Data Privacy Data Security Death Demographics Disability Diversity Employee Employee Engagement Engagement Ethnic Ethnicity Gender General Data Protection Regulation Health and Safety Health Care Healthcare Hire Hiring Hispanic Human Capital Human Resources Human Trafficking Incident Injuries Injury LGBTQ Pay for Performance Privacy Product Quality Product Safety Recall Recruit Recruitment Reimbursement Retention Retirement Safety Satisfaction Skill Skills Social Stakeholder Supplier Supply Chain Talent Training Union Volunteer Women Workforce Action Plan Anti-corruption Antitrust Assessment Assurance Attorney General Audit Board Oversight Bonus Bribe Bribery Chronic Class Action Lawsuit Classified Classified Board Clawback Commitment Conflict of Interest Corporate Governance Corporate Purpose Department of ESG Ethics Executive Compensation Expert Fraud Goals Governance Hedging Incentive Incentivize Independence Independent Innovate Innovation Innovative Investigation Key Performance Indicator Lawsuit Lead Independent Director Leadership Litigation Long-term Majority Mission Oversee Oversight Plaintiff Pledging Procurement Proxy Contest Purpose Quality Standard R&D Reputation Reputational Reputational Risk Research and Development Responsibility Responsible Stockholder Engagement Stockholder Outreach Strategy Sustainability Sustainable Targets Tax Tax Gross Up Tenure Transparent

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

.

On May 25, 2022, Tandem Diabetes Care, Inc. (the “Company”) held a virtual Annual Meeting of Stockholders (the “Annual Meeting”). There were 63,939,108 shares of the Company’s common stock (“Common Stock”) outstanding on March 29, 2022, the record date for the Annual Meeting. At the Annual Meeting, 57,273,934 shares of Common Stock were present virtually or represented by proxy.

The following tables set forth the final results of the voting for the matters voted upon at the Annual Meeting. These matters are described in more detail in the Company’s definitive proxy statement, filed with the Securities and Exchange Commission (the "SEC") on April 13, 2022 (the “Proxy Statement”).

Proposal 1: The election of two Class III directors to serve either a one-year term to expire at the 2023 annual meeting of stockholders or a three-year term to expire at the 2025 annual meeting of stockholders. The stockholders elected the two Class III directors by the following votes:

Name of Director	For	Against	Abstain	Broker Non-Votes

Peyton R. Howell	52,173,681	598,147	24,915	4,477,191
John F. Sheridan	51,794,146	977,941	24,656	4,477,191

Proposal 2: To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to provide for the annual election of directors and the phased elimination of the classified board structure. The proposal received the following votes:

For						Against						Abstain						Broker Non-Votes

52,752,267						29,545						14,931						4,477,191

Proposal 3: To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as described in the Proxy Statement. The proposal received the following votes:

For						Against						Abstain						Broker Non-Votes

51,930,214						815,070						51,459						4,477,191

Proposal 4: The ratification of the appointment of Ernst & Young LLP to serve as the Company's independent registered public accountant for the year ending December 31, 2022. The proposal received the following votes:

For						Against						Abstain						Broker Non-Votes

55,953,312						1,298,596						22,026						0